GV-backed cancer drug developer Kronos Bio floated above its range in an upsized offering and saw its shares soar in price post-IPO.
US-based oncology drug developer Kronos Bio went public in a $250m initial public offering on the Nasdaq Global Select Market on Friday, providing an exit for internet and technology conglomerate Alphabet.
The size of the offering was increased from almost 10.3 million shares to more than 13.1 million and they were priced at $19.00 each, above the $16 to $18 range set by the company last week. Its shares closed at $27.07 on Friday, valuing the company at…
